Triple-Drug attack before prostate surgery shows promise in early trial
NCT ID NCT06861192
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two drugs—fasudil hydrochloride and a PD-1 inhibitor—to standard hormone therapy before prostate cancer surgery can better shrink or eliminate tumors. About 83 men with locally advanced or limited metastatic prostate cancer will receive either the combo or a placebo before their operation. The goal is to see if more patients have no visible cancer left in the removed prostate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fasudil hydrochloride, PD-1 inhibitor (triprilizumab), and androgen deprivation therapy
- What this could lead to
- If successful, this combination could become a new standard neoadjuvant treatment before prostate cancer surgery, potentially improving the chance of eliminating or shrinking tumors.
- What could go wrong
- This is an early-phase trial with only 83 participants, so results may not apply broadly. The added drugs may cause side effects like immune reactions or blood pressure changes, and the benefit over standard hormone therapy alone is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongda Hospital
RECRUITINGNanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug cocktail before surgery curb prostate Cancer's return?
- Mapping Cancer's next move: study tracks where prostate cancer returns after aggressive radiotherapy
- AI takes on radiologists in prostate cancer detection trial
- Triple attack on prostate cancer: drug, surgery, and radiation aim to stop spread
- New pill combo aims to boost prostate cancer cure rates
- New study aims to improve prostate cancer detection for trans community